Please provide your email address to receive an email when new articles are posted on . Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SCOTTSDALE, Ariz. — A novel therapeutic approach ...

Myasthenia gravis is a lifelong (chronic) autoimmune condition, which means that the body’s immune system attacks its own healthy cells. Most people with generalized myasthenia gravis (gMG) have ...

Viridian Therapeutics Inc. has disclosed a preclinical portfolio of neonatal Fc receptor (FcRn) inhibitors designed for next-generation treatment of antibody-mediated autoimmune diseases.

SAVANNAH, Ga. -- Investigational nipocalimab plus standard of care achieved sustained reductions in immunoglobulin G (IgG) and appeared to be safe for adolescent patients with generalized myasthenia ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing ...